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Abstract
 .P-glycoprotein Pgp is a plasma membrane protein known as an ATP-dependent drug-efflux pump that confers
 .multidrug resistance to tumor cells. Structural analysis of Pgp was investigated by circular dichroism CD for the first time
and in combination with amino acid sequence analysis. CD of highly purified Pgp from human, rat and murine
Pgp-overexpressing drug resistant cells revealed slight variations in the spectral shape when recorded in the presence of
 .dodecyl maltoside DM . These species-dependent variations in CD shapes resulted from the interaction of the oligosaccha-
 .ridic part with the protein core since they were abolished either in the presence of sodium dodecyl sulfate SDS or after
deglycosylation, the latter not altering the Pgp ATP-dependent drug transport activity. Whatever the level of Pgp
 .glycosylation and the detergent used SDS or DM , the content in secondary structure deduced from deconvolution of CD
spectra is almost the same for the three sources of Pgp and estimated to 43% a-helix, 16% b-sheet, 15% b-turn and 26% of
other structures. These data, which constitute the first report of Pgp structure analysis by circular dichroism, are consistent
with the 48% a-helix and 16% b-sheets global contents predicted by using recently reported efficient secondary structure
prediction methods. This consistency reinforces the reliability of the probable nature and localization of predicted Pgp
secondary structure elements. This provides a good framework for precise 3D structure modeling of Pgp by homology with
proteins of known 3D structure, as it is illustrated here for the A motifs of the ATP-binding domains of Pgp. q 1998
Elsevier Science B.V. All rights reserved.
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1. Introduction
 .P-glycoprotein Pgp is a plasma membrane pro-
tein overexpressed in cancer cells which acquired
multidrug resistance after prolonged treatment with
anticancer drugs. Pgp is encoded by a small family of
 .two genes in human MDR1 and MDR2 , and three
genes in rodents mdr1a or mdr3, mdr1b or mdr1
.and mdr2 , but only mdr1 genes encode Pgp that is
w xinvolved in the MDR phenotype 1,2 . Human Pgp is
composed of 1280 amino acids while murine and rat
Pgp contain 1277 amino acids. Pgp is an N-glyco-
sylated protein but its level of glycosylation depends
on the species: murine Pgp is poorly glycosylated
 .apparent mol.wt. of 140 kDa in comparison to rat
 w x.and human Pgp apparent mol.wt. of 170 kDa, 3 . It
is believed that Pgp functions as an ATP-dependent
drug efflux pump that extrudes drugs out of cells.
This has been evidenced in vitro, on either cultured
cells or isolated plasma membrane vesicles or recon-
w xstituted Pgp liposomes 3 , and the references
.therein . Glycosylation of Pgp has been generally
reported not to be directly required for Pgp function-
w xing 4 . However, a recent study indicates that glyco-
sylation may be involved in drug transportation in
w xresistant cells 5 , thus raising again the question of
the role of glycosylation. A couple of models for the
w xfunction of Pgp has been proposed 6 , but the mech-
anisms by which Pgp reduces the intracellular drug
concentration and the process of ATP coupling to
drug transport remain unclear. The identification of
structurerfunction relationships in Pgp has relied
upon the scrutiny of Pgp primary sequence and on
biochemical and genetic analysis. Pgp consists of two
halves, each containing six predicted hydrophobic
membrane-spanning segments followed by a cyto-
plasmic domain including the nucleotide-binding do-
 .main NBD with the characteristic A and B motifs
w xdescribed by Walker et al. 7 . Putative structural
models for the NBDs of Pgp based on the known
crystal structures of other NBDs have also been
w xproposed 8,9 . The sequences and domain organiza-
tion of Pgp are typical of the ATP-binding cassette
 .ABC superfamily of active transporters including
w x w xyeast 7 and protozoan parasite 10 drug trans-
porters, a series of different members from eukaryotic
proteins like the cystic fibrosis gene product CFTR
—cystic fibrosis transmembrane conductance regula-
.tor , and the recently found basolacteral CFTR coun-
terpart EBCR epithelial basolacteral chloride con-
w x. w xductance regulator, 11 to bacterial transporters 12 .
Recent structural analyses by electron microscopy
provide the first view of the 3D structure of both
detergent-solubilized and lipid-reconstituted purified
w x  .Pgp 13 . Although the resolution was low 2.5 nm ,
this initial structure revealed the presence of a large
central aqueous chamber which appeared closed to
the cytoplasmic face and open to the lipid phase.
Moreover, the two nucleotide binding domains have
been attributed to two lobes exposed to the cytoplas-
mic face of the membrane. Recent FTIR investigation
of purified Pgp reconstituted into liposomes provides
an estimation of Pgp secondary structure, with 32%
a-helix, 26% b-sheet, and 13% unordered structure
w x14 . In addition, Pgp secondary structure was not
significantly altered in the presence of ATP and
drugs while these compounds induced conformational
w xchanges of Pgp 14 . Although these studies provided
important information, more detailed structural data
are necessary for understanding the molecular mecha-
nisms of drug transportation by Pgp. A prerequisite
for Pgp structural and functional studies is the avail-
ability of a large amount of highly purified and active
Pgp. We have recently developed an efficient proce-
 .dure to prepare pure Pgp )99% by combining
SDS solubilization and ceramic hydroxyapatite chro-
w xmatography 3 . After exchange of SDS with dodecyl
w xmaltoside and reconstitution into liposomes 15 , Pgp
exhibited both ATPase and drug transport activities.
This preparation of Pgp is virtually devoid of lipids
and it is therefore particularly useful for structural
 .studies such as circular dichroism CD .
CD spectroscopy is an excellent tool for monitor-
ing protein and peptide conformation and the modifi-
cations that may occur in response to environmental
changes. The far-UV CD of proteins is sensitive to
their secondary structure and can therefore be used to
determine the relative amounts of the different sec-
ondary structural elements. For soluble proteins, CD
spectra are typically analyzed by deconvolution using
a basic set of spectra to extract the percentages of
wa-helix, b-sheet, b-turn and other conformations for
w xxreviews, see Refs. 16,17 . Analysis of CD spectra of
membrane proteins in the presence of lipids is com-
plicated by differential light scattering and absorption
flattering. However, membrane proteins solubilized
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by detergents generally present no special difficulties
wand CD data are analyzed as soluble proteins see
w xxreviews 17,18 . A particular difficulty arises from
the presence of protein glycosylation which may
w xchange the CD spectra 19 and thus analysis of CD
spectra of Pgp should be performed carefully.
CD spectroscopy has been greatly improved in
recent years and it is possible to analyze the spectrum
of a protein for secondary structure with high reliabil-
ity. One of the powerful methods of analysis is the
 w x.variable selection method VARSELEC 16,20,21 :
w xit uses singular decomposition for deconvolution 22
to systematically analyze the effect that each protein
which belongs to a basic set exerts on the secondary
structure of the sample protein. Reference proteins
that present unwanted CD contributions are discarded
so as to reach a total secondary structure close to
100%. This method has been reported to reach corre-
lation coefficients of 0.97 for a-helix, 0.76 for b-
sheet, 0.49 for b-turn and 0.86 for other structures
when the estimation of secondary structure from CD
data obtained for wavelengths down to 178 nm is
compared to X-ray structure data for the sixteen
w xproteins in the data base 21 . Although CD analysis
gives an indication of the percentage of secondary
structure, it does not provide any evidence about the
localization of structured stretches along the amino
acid sequence. In this context, the analysis of the
structure of a protein can be usefully completed using
secondary structure prediction methods.
Secondary structure prediction methods have made
significant progresses in recent years by taking into
account the multiple alignment of related proteins
and thanks to the increasing number of resolved
protein structures. The most efficient methods are
now reliable at a 70% level of accuracy for three
w w xxconformational states for a review, see Ref. 23 . By
using the combination of two methods based either
 w x.on neural networks PHD, 24 or on Self-Optimized
 .Prediction form Alignments SOPMA , the accuracy
w xrises up to 82% for jointly predicted residues 25 .
Thus, the secondary structure predictions are now
reliable enough to derive relevant structural proper-
ties. Moreover, it is well admitted that a protein,
which presents high homologies in sequence and in
secondary structure with a protein of known 3D
w xstructure, likely adopts the same global fold 26 .
Hence, modeling by structure homology can be un-
dertaken.
In the present study, we report for the first time the
CD analysis of purified, detergent-solubilized human,
rat and murine Pgp. It allows us to specify the effect
of glycosylation on Pgp structure and its relationship
with Pgp functioning. Moreover, deconvolution of
CD spectra allowed the estimation of the secondary
structure contents of Pgp which is consistent with
that obtained by sequence analyses. This reinforces
the reliability of the Pgp secondary structure predic-
tion data that are also reported here and which consti-
tute a good basis for further structure–function rela-
tionship studies and molecular modeling.
2. Materials and methods
2.1. Materials
 .Cell culture media DMEM and RPMI-1640 were
from BioWHITTAKER and fetal calf serum was
from Sigma. Dodecyl maltoside, tunicamycin, egg
 .yolk L-a-phosphatidic acid PA , egg yolk L-a-phos-
 .phatidylcholine PC and routine chemicals were from
Sigma. Recombinant PNGase F was from Genzyme
 .  .Cambridge, MA . Sodium dodecyl sulfate SDS
was from Serva. Prepacked ceramic hydroxyapatite
 .HPLC column 0.7=5.2 cm and Bio-beads SM2
were from Bio-Rad. HPLC was performed on a
Waters apparatus equipped with a 991 Photodiode
Array Detector.
2.2. Cell culture
The highly drug-resistant murine lymphoid
leukemia P388rADR25 resistant to 25 mgrml adri-
. amycin , rat hepatoma AS30-DrCOL10 resistant to
.10 mgrml colchicin , and human lymphoblastic
leukemia CEMrVLB5 resistant to 5 mgrml vinblas-
.tine cell lines were established and maintained as
w xdescribed previously 3 . To inhibit the N-linked
glycosylation of Pgp, AS30-DrCOL10 cells were
grown in the presence of 2 mgrml tunicamycin for 5
days prior to harvesting.
( )M. Dong et al.rBiochimica et Biophysica Acta 1371 1998 317–334320
2.3. Protein purification and detergent exchange
Preparation of plasma membranes from highly re-
sistant cell lines and purification of Pgp by SDS
solubilization and hydroxyapatite chromatography
w xwere described previously 3,15 . This procedure
 .yields large amounts of highly purified Pgp )99%
and was also used to prepare pure non-glycosylated
Pgp from tunicamycin-treated AS30-DrCOL10 cells.
The removal of SDS from Pgp was done by exchang-
ing it with dodecyl maltoside using ceramic hydroxy-
apatite chromatography according to the procedure
w xreported elsewhere 3,15 . In brief, Pgp purified in
the presence of 1% SDS was loaded onto the
hydroxyapatite column equilibrated with 50 mM
 .sodium phosphate pH 7.0 containing 0.1% DM and
1 mM DTT. After extensive washing with 0.22 M
phosphate for 40 min, Pgp was eluted with 0.7 M
phosphate containing 0.1% DM and 1 mM DTT. This
procedure allows the complete removal of SDS from
w xPgp 15 . For the preparation of samples for CD
measurements, the eluted Pgp fractions were desalted
and concentrated by ultrafiltration using Centricon-30
 .devices Amicon, 30 kDa cut-off .
2.4. Enzymatic deglycosylation of Pgp
To remove oligosaccharides from purified Pgp,
 .100 mg rat AS30-DrCOL10 Pgp 0.2 mgrml in 10
 .mM sodium phosphate pH 7.0 containing 1 mM
DTT, 1 mM phenylmethanesulfonyl fluoride and
0.1% DM, were incubated for 18 h with 10 Urml
PNGase F at 378C. The protein sample was then
applied onto the ceramic hydroxyapatite column equi-
 .librated with 0.22 M phosphate pH 7.0 containing
0.1% DM and 1 mM DTT. Pgp was bound to the
column whereas PNGase F and the cleaved oligo-
saccharides passed through the column. After exten-
 .sive washing of the column 40 min , deglycosylated
Pgp was eluted as reported above for detergent ex-
change.
2.5. Reconstitution and acti˝ity assays
Pgp was reconstituted into liposomes by the method
w xdeveloped by Rigaud et al. 27 as detailed previously
w x3 . In brief, 1.375 ml of buffer containing 20 mM
Tris–HCl, pH 7.4, 75 mM NaCl, 1 mM DTT and 0.5
mM EDTA was added to a dry lipid film PC 25 mg,
.PA 2.5 mg and the mixture was sonicated on ice
until the milky phase became transparent about 15
.min . To a 100 ml aliquot of this preparation, 610 ml
of buffer and 40 ml of 10% dodecyl maltoside were
sequentially added under constant stirring at room
temperature. After 15 min, 250 ml of 0.2 mgrml
purified Pgp were slowly added and the mixture was
incubated under constant agitation for another 15
min. Bio-beads were added stepwise to remove the
detergent: 40 mg for 45 min, 40 mg for 45 min, 40
mg for 30 min and finally, 40 mg for 30 min.
Measurements of Pgp activities were done on aliquots
of the supernatant containing reconstituted proteo-
liposomes. The assay of Pgp ATPase activity was
measured by the NADH fluorimetric method detailed
w xpreviously 3 . Drug transport activity of reconstituted
Pgp was assayed using the protocol described by
w xHorio et al. 28 .
2.6. Analytical methods
Protein samples were analyzed by SDS-PAGE on
an 8% polyacrylamide gel under reducing conditions
w xas described by Laemmli 29 and detailed previously
w x30 except that samples were not heated before
loading. Gels were silver-stained according to Bloom
w xet al. 31 . Protein concentration was estimated by the
w xcolorimetric method of Peterson 32 which allows
the measurement of protein in the presence of SDS or
DM using bovine serum albumin as the reference
protein. Data were cross-checked by UV absorption
spectroscopy at 280 nm using molar extinction coef-
ficients of 1536 and 5600 for tyrosine and trypto-
w xphane residues, respectively 33 , and taking into
account the Pgp contents in these amino acids for
each species.
2.7. CD measurement
CD spectra were recorded on a Jobin-Yvon CD6
spectrometer calibrated with ammonium D-10-
camphorsulfonate according to Jobin-Yvon technical
specifications. All calculations were made using the
CD6 spectrum processing software. Protein samples
at a concentration of 0.2–0.8 mM were scanned at
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room temperature in dichroically neutral quartz cu-
 .vettes Hellma with a path length of either 0.1 or
0.02 cm. Spectra were recorded in the wavelength
range 183–250 nm or 190–250 nm in 0.2 nm incre-
ments with a 2 s integration time. Spectra were
automatically averaged over eight scans. Sample
spectrum without protein was subtracted and the
baseline-corrected spectra were smoothed by using a
third-order least squared polynomial fit. Following
baseline correction, the observed ellipticity was con-
w x verted into a mean residue molar ellipticity u deg
2 y1. w x  .cm dmol , using the relationship u sur lcN ,
where u is the observed ellipticity, l is the path
length in millimeters, c is the peptide molar concen-
tration, and N is the number of residues in the
protein. All calculations were performed using the
CD6 spectrum processing software.
2.8. E˝aluation of protein secondary structure from
CD spectra
The secondary structure percentages were esti-
mated from the measured ellipticities using the Di-
croprot software available by anonymous ftp at
. w xftp.ibcp.fr into which the Varselec method 16,20,21
has been integrated. The VARSLC1 program was
kindly provided by W.C. Johnson Jr. In brief, this
deconvolution method assumes that the protein CD
spectrum is a sum of the contributions of five sec-
ondary structures scaled by the mole fraction: a-helix,
parallel and anti-parallel b-sheets, b-turn and other.
To accurately estimate the percentage of each sec-
ondary structure in the analyzed protein, reference
proteins which exhibit features contributing to the
CD that are not found in the sample protein should be
eliminated from the basic set of 33 reference proteins
of known secondary structure. This is obtained by
systematically fitting the sample protein with the
subsets of reference proteins by removing three pro-
teins at a time. The results of all combinations are
checked for a satisfactory solution that follows selec-
tion criteria among which the most important ones
 .are: i the total of all five secondary structures
 .should be between 0.96 and 1.05; ii no negative
 .secondary structure should be lower than y0.05; iii
the a-helix fraction should not change significantly
from the original analysis with all the 33 reference
 .proteins; iv the calculated CD spectrum should
reasonably fit the experimental spectrum low root-
.mean-square residual . The combination of proteins
that meet these criteria and that eliminate the fewest
proteins from the basic set are then averaged to give
the reported percentage of each secondary structure.
2.9. Sequence analysis and secondary structure pre-
diction
Alignment of mouse, rat and human Pgp se-
quences were achieved with the CLUSTALW pro-
Fig. 1. Circular dichroism spectra of human Pgp in the presence
 .  .of dodecyl maltoside DM or sodium dodecyl sulfate SDS .
Purified human Pgp from CEMrVLB5 cells in 10 mM sodium
 .phosphate buffer pH 7.0 containing 1% DM or 1% SDS was
prepared as described in Section 2. Protein samples at a concen-
tration of 0.8 mM were scanned for 8 times from 183 to 250 nm
at 0.2 nm increments, integration time 2 s, in a dichroically
neutral quartz cuvette with a path length of 0.2 mm. The base-
lines were corrected by subtraction of the buffer spectrum. No
smoothing was applied. Far-UV circular dichroism spectra are
w x presented in terms of residue mean molecular ellipticity u in
2 y1.deg cm dmol .
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w x gram 34 with default parameters fixed and variable
gap penalty set to eight, filtering levels set to 1.5 and
.window width fixed to 10 . The putative motifs of
nucleotide-binding sites were searched for with the
help of the protein sequence analysis server
 .http:rrwww.ibcp.frrpredict.html and the Prosite
w xdictionary of signatures and potential sites 35 . The
secondary structure of mouse, rat and human Pgp
sequences Swissprot code MDR1_MOUSE,
.MDR1_RAT and MDR1_HUMAN, respectively
w xwas predicted by using both PHD 24 and SOPMA
w xmethods 25 . Briefly, both methods scan a sequence
database in order to extract homologous proteins and
take advantage of the multiple alignment of these
related proteins to improve the prediction accuracy.
They differ in their predictive algorithm since the
PHD method uses neural networks whereas SOPMA
uses a similarity matrix and an auto-optimization
procedure. The structure superimpositions were per-
w xformed with the ANTHEPROT 2.0 software 25 .
The fit was carried out on the a carbons of 22 amino
acids in the alignment of NBDs with known struc-
tures. The averaged root mean square deviation was
calculated as follows:
N
2RMSDs d yd .) i j
where N is the number of atoms, i and j are the
number of the superimposed atoms, and d is the
distance between atoms i and j.
The graphic display of molecules was done with
w xeither Rasmol 36 or ANTHEPROT.
All these analyses were performed through the
Protein Sequence Analysis service available on the
 .network http:rrwww.ibcp.frrpredict.html .
Table 1
Percentages of secondary structure of human, murine, and rat Pgp estimated from CD data and predicted from their sequences
 .Pgp species Wavelength range nm a-helix b-sheet b-turn Other Total
Anti-parallel Parallel
CD in DM
Human Pgp 183–250 43"1 10"1 6"1 15"1 26"2 101"4
Human Pgp 190–250 41"1 11"1 7"1 15"1 27"2 101"3
Murine Pgp 190–250 39"1 12"1 7"1 15"1 27"2 99"4
Rat Pgp 190–250 39"1 11"1 7"1 14"1 26"1 98"3
a .Rat Pgp non-glycosylated 190–250 38"1 12"1 6"1 15"1 27"1 99"4
b .Rat Pgp deglycosylated 190–250 39"1 12"1 7"1 15"1 28"2 101"4
CD in SDS
Human Pgp 183–250 41"1 10"1 6"1 15"1 27"2 99"4
Human Pgp 190–250 39"1 11"1 6"1 15"1 27"2 99"4
Murine Pgp 190–250 39"1 11"1 6"1 15"1 27"2 98"4
Rat Pgp 190–250 38"1 11"1 6"1 14"1 27"2 96"4
Pgp species a-helix b-sheet Remaining structures
Prediction from sequence
Human Pgp 49 16 35
Murine Pgp 48 16 36
Rat Pgp 49 16 35
Deconvolution of CD spectra was done using the Varselec method as detailed in Section 2. For all Pgp spectra, satisfactory analyses were
achieved after elimination of the same three proteins from the basic set of 33 reference proteins: poly glutamic acid, triose phosphate
isomerase and hemerythin. Data are presented in the top panel as mean percentage of secondary structure with the corresponding standard
 .deviation. The predicted percentages of secondary structure bottom panel were calculated on the basis of the average between the data
obtained from both SOPMA and PHD methods on the whole sequences.
aRat Pgp purified from tunicamycin-treated AS30-DrCOL5 cells.
bRat Pgp digested with PNGase F as described in the text.
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3. Results
3.1. CD of Pgp
Human Pgp from CEMrVLB5 cells was solubi-
lized and purified in the presence of SDS and the
complete removal of SDS was achieved by exchang-
 .ing with dodecyl maltoside DM . Fig. 1 shows that
the CD spectra of purified human Pgp in the presence
of either 1% SDS or 1% DM are both typical of
well-folded proteins and the molar ellipticity per
residue is in the range that can be expected. These
spectra are presented without smoothing to show the
accuracy of the measurements even though they were
performed down to 183 nm and in the presence of
detergent micelles. Both spectra are in the same
amplitude range and present a maximum at 193 nm.
The spectrum obtained when the protein is in the
presence of SDS crosses the zero ellipticity axis at
200 nm and exhibits two minima at 208 nm and 222
nm, which are typical of a-helical conformation. In
the presence of DM, the Pgp spectrum is less charac-
teristic with two blunt minima near 208 and 222 nm,
the former being less intense than that for the protein
in SDS while the intensity of the latter is identical in
the presence of DM or SDS. In addition, relative to
that of Pgp in SDS, the spectrum of Pgp in DM is
red-shifted by 3 nm at the level of zero ellipticity.
Nevertheless, despite the visible differences in the
shape of CD spectra in SDS and DM, analysis of the
spectra for secondary structure estimation did not
reveal significant differences in secondary structure
 .contents Table 1 . These findings suggest a slight
effect of SDS on the Pgp secondary structure and the
spectral differences may be attributed to some distur-
bance of the Pgp tertiary structure in SDS.
Fig. 2. Comparison of CD spectra of human, rat and murine Pgp
 .  .in the presence of dodecyl maltoside A and SDS B . Pure Pgp
samples were in 10 mM sodium phosphate, pH 7.0, containing
 .  .1% dodecyl maltoside A or 1% SDS B at a protein concentra-
tion of 0.5 mM. All far-UV CD spectra were recorded from 190
to 250 nm using 1 mm path length cuvette average of eight
.scans and smoothed after subtraction of the buffer spectrum.
Dashed line: human Pgp from lymphoblastic leukemia
CEMrVLB5 cells; solid line: rat Pgp from hepatoma AS30-
DrCOL10 cells; dot line: murine Pgp from lymphoid leukemia
P388rADR25 cells.
Estimation of the secondary structure content re-
ported in Table 1 was made using the Varselec
method following the guideline and recommendations
reported by Johnson and co-workers see Section 2
.and legend of Table 1 . It has been pointed out that
CD data yields statistically accurate estimates of mul-
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tiple classes of secondary structure only if the data
extend down to 184 nm. To comply with this require-
ment, narrow CD cells together with concentrated
protein solutions were used to obtain a good signal to
noise ratio. However, it is well known that membrane
proteins tend to aggregate in a time-dependent man-
ner once concentrated. Thus, to avoid any risk of
aggregation, CD spectra were routinely recorded us-
ing less concentrated Pgp and larger cuvettes, though
these conditions allowed the recording of down to
190 nm only to maintain a reasonable signal to noise
ratio. In fact, data reported in Table 1 show that for
human Pgp recorded in SDS and in DM, the trunca-
tion of CD spectra at 190 nm resulted in only slight
underestimation of the a-helix contents while the
percentages of other structures remained almost iden-
tical. However, these variations are not significant
from a statistical point of view. For all these reasons,
the Pgp comparisons reported below were made after
analysis of CD spectra recorded from 190 to 250 nm.
To address the question of whether there are some
differences in the structure of Pgp from various
species, we compared the CD spectra of murine and
rat Pgp with the human one in the presence of either
 .  .DM Fig. 2A or SDS Fig. 2B . In the presence of
 .DM, the spectrum of rat Pgp solid line is very
similar in shape to that of human Pgp dash line, Fig.
.2A . In contrast, although the three spectra exhibit a
maximum at 193 nm, the spectrum of murine Pgp
 .dot line is rather different from that of rat and
 .human Pgp: i both minima at 208 nm and 222 nm
are well defined and are lower than those of rat and
 .human Pgp; ii the murine Pgp spectrum is blue-
shifted relatively to the human and rat ones with zero
ellipticity at 200 nm instead of 203 nm for rat and
human Pgp. Contrary to what is observed in DM, the
spectra obtained for murine, rat and human Pgp are
almost identical when recorded in the presence of
 .SDS Fig. 2B : same amplitudes, a deep minimum at
208 nm and a shoulder at 222 nm, zero ellipticity at
200 nm. Although the spectrum of murine Pgp is
different from both rat and human Pgp spectra in the
presence of DM, the calculated secondary structure is
close to that of the two other sources of Pgp see
.Table 1 . Moreover, data in Table 1 show that there
is also no significant difference between the sec-
ondary structure obtained in the presence of DM and
that obtained in the presence of SDS for the three
species. It could be concluded at this step that the
differences observed in the shape of Pgp CD spectra
in DM may be related to some tertiary structure
variation.
3.2. Effects of glycosylation on Pgp acti˝ity
It should be reminded that the main difference
between murine Pgp and the rat and human ones lies
at the level of glycosylation, the former being much
less glycosylated with an apparent mol.wt. of 140
. kDa by electrophoresis than the two others apparent
. w xmol.wt. of 170 kDa as evidenced previously 3 . To
evaluate the influence of glycosylation on the struc-
ture and function of Pgp, oligosaccharide-free Pgp
was prepared either by enzymatic treatment with
PNGase F or by culturing AS-30DrCOL10 cells in
the presence of tunicamycin prior to purification see
.Section 2 . As evidenced from the SDS-PAGE analy-
 .sis shown in Fig. 3, the native rat Pgp lane 1
migrated as a 170 kDa band, whereas both PNGase
 .F-treated rat Pgp called deglycosylated Pgp and Pgp
purified from tunicamycin-treated cells called non-
.glycosylated Pgp moved as 140 kDa proteins. This is
Fig. 3. Analysis of deglycosylated and non-glycosylated rat Pgp
by SDS-PAGE. Deglycosylation was performed by PNGase F
digestion of native rat Pgp as detailed in Section 2. Non-glyco-
sylated Pgp was purified from tunicamycin-treated AS30-
DrCOL10 cells, as detailed in Section 2. Samples were run on
an 8% SDS-PAGE gel followed by silver staining. Lane 1,
purified glycosylated rat Pgp from AS30-DrCOL10 cells, 1 mg;
lane 2, deglycosylated rat Pgp, 0.2 mg; lane 3, non-glycosylated
rat Pgp, 0.2 mg. MW, molecular weight standard, 0.5 mg for
each band.
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in agreement with the expected molecular weight
calculated from the amino acid composition of Pgp
 .141 299 Da and shows that oligosaccharide-free
Pgp can be obtained by either way. From a functional
point of view, deglycosylated Pgp reconstituted into
liposomes presented a 5-fold increase in ATPase
activity when compared to normal Pgp typically
1040"100 nmol ATPrminrmg deglycosylated Pgp
and 200"50 nmol ATPrminrmg Pgp for rat AS-
. w3 x30DrCOL10 Pgp , while ATP-dependent H -vinb-
lastine uptake activity was slightly lower for deglyco-
 .sylated Pgp 81"4 pmolr20 minrmg protein than
 .normal Pgp 120"10 pmolr20 minrmg protein .
As discussed below, these differences in activities are
likely due to the ratio of right-side out and inside out
configuration of reconstituted Pgp. Nevertheless,
these results demonstrate that normal and deglycosy-
lated Pgp used in the CD experiments were active
after reconstitution into liposomes, although they did
not exhibit ATPase activity in the detergent-solubi-
w xlized state because of the absence of lipids 37 .
Moreover, when cultured in the presence of tuni-
camycin, AS-30DrCOL10 cells producing non-gly-
cosylated Pgp survive in the presence of 10 mgrml
colchicin Baggetto and Dong, unpublished observa-
.tion . These data strongly suggest that the oligosac-
charidic part of Pgp is not essential for it to function.
3.3. Effect of glycosylation on Pgp structure
CD spectra of oligosaccharide-free rat Pgp recorded
in the presence of DM are reported in Fig. 4A in
comparison with glycosylated rat Pgp in DM and in
SDS. As can be expected, the spectrum of Pgp
purified from tunicamycin-treated cells non-glyco-
 .Fig. 4. Effects of glycosylation on CD of Pgp. A Comparison of
 .the CD spectra of glycosylated rat Pgp in 1% DM solid line and
 .in 1% SDS dash line with that of oligosaccharide-free rat Pgp
in 1% DM obtained either by enzymatic treatment of purified
 .Pgp with PNGase F long dash–short dash line or by Pgp
purification from tunicamycin-treated rat AS30-DrCOL10 cells
 .  .dot–dash line , as detailed in Section 2. B Comparison of the
 .CD spectra of murine P388rADR25 Pgp in 1% DM dot line
 .and in 1% SDS dash line with that of non-glycosylated rat Pgp
purified from tunicamycin-treated AS30-DrCOL10 cells dot–
.dash line . Protein concentration, buffer used and recording of
spectra were as described in the legend of Fig. 2.
.lsylated Pgp is almost identical to that of PNGase
 .F-digested Pgp deglycosylated Pgp , with a mini-
mum at 203 nm and a shoulder at 222 nm, the zero
ellipticity being at 200 nm. The shape of these oligo-
saccharide-free Pgp CD spectra is rather different
from that of glycosylated Pgp in the presence of DM,
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although deconvolution analysis by Varselec did not
reveal significant differences in the contents of each
secondary structure. However, the spectral differ-
ences between the glycosylated Pgp and the oligo-
saccharide-free one remain low, indicating that the
contribution of the sugar part of Pgp to the CD
spectrum is limited. Taken together, these results
indicate that glycosylation of Pgp has little effect on
the secondary structure of the protein but certainly
induces some local conformational changes in the
structure of Pgp. Interestingly, the CD spectrum shape
of oligosaccharide-free Pgp is close to that of glyco-
sylated Pgp in the presence of SDS. This indicates
that the conformation of Pgp may be modified in the
same manner when oligosaccharides are not present
or when their interaction with the core protein is
abolished by SDS.
As stated above, murine Pgp is naturally much less
glycosylated than human and rat Pgp, although some
glycosylation level was revealed Dong and Baggetto,
.unpublished results . The comparison of the CD spec-
 .trum of murine Pgp in DM dot line in Fig. 4B with
that of non-glycosylated rat Pgp in DM dot–dash
.line obviously shows that the shapes of both spectra
are very similar. Here again, both spectra are close to
 .that of rat Pgp in the presence of SDS dash line and
the calculated secondary structure from these three
 .spectra did not show significant differences Table 1 .
It is clear from these data that the particular shape of
murine Pgp spectrum in DM evidenced by its com-
 .parison with rat and human Pgp Fig. 2A is due to
its low level of glycosylation. In conclusion, the
shape of Pgp CD spectra depends on the presence of
glycosylation, indicating that the sugar part of Pgp
interacts with the protein core. As all the Pgp species
gave superimposable CD spectra in the presence of
SDS while they are rather different in DM, it is
concluded that SDS abolishes the interaction between
the Pgp sugar part and the protein core.
3.4. Secondary structure of Pgp predicted from its
sequence
The secondary structure prediction of the whole
Pgp sequence by SOPMA and PHD methods allows
the global estimations of Pgp secondary structure
 .Table 1 . The results are very similar for the three
Pgp species and yield an average content of 48%
a-helix, 16% b-sheet and 36% coil. These values are
rather close to those obtained from CD experiments
for three states only 43% a-helix, 16% b-sheet and
.41% others when considering the most reliable esti-
mation deduced from deconvolution of human-Pgp
CD spectra recorded in the 183–250 nm range Table
.1 . This consistency of data reinforces the reliability
of secondary structure estimation by both approaches
and encourages us to further state precisely the local-
ization of stretches of secondary structure along the
amino acid sequence. Data presented in Fig. 5 are the
result of a careful sequence analysis described as
 .follows. i Since secondary structure prediction
methods are not very efficient for membrane regions,
the 12 transmembrane segments were deduced from
w xprevious work 39 where they were predicted as
 .a-helices. ii Intermembrane regions longer than 40
residues were submitted as individual requests to
prediction. Thus, eight major regions were distin-
guished on the human Pgp region 1, 1–51; region 2,
Fig. 5. Secondary structure of human, murine and rat Pgp predicted from their respective sequence. The three sequences were extracted
w xfrom Swissprot 33 38 and named with their corresponding code entry: HUM, MDR-HUMAN; MOU, MDR_MOUSE; RAT,
w xMDR1_RAT. The sequences were aligned according to the CLUSTALW program 34 with default parameters. A motifs of the
nucleotide-binding domains are shown with a heavy solid line. The twelve transmembrane domains defined according to the previous
w xwork of Chen et al. 39 , are shown under numbered brackets form 1 to 12. Alpha helices are represented with letters in reversed color
into a black box, beta sheets are shown in grey boxes, and aperiodic regions in white boxes. Secondary structures are indicated if both
 .prediction methods PHD and SOPMA, see Section 2 predict the same conformational state. For residues that were predicted as an
isolated state within long regular secondary structures, a smoothing was performed as follows: the residue is converted into the
 .  .surrounding conformational state if i it exhibits a good calculated tendency to fit with the surrounding state, and ii there are at least
two residues at both sides which present the same state. Glycosylation positions reported in the literature are located at N91, N94, N99,
w xand N296 for human Pgp, N91 and N96 for mouse Pgp, and N91, N96, and N295 for rat Pgp, respectively 39,40 . Identical and similar
 .  .amino acids for the three sequences are symbolized by a star ) and a dot fl , respectively.
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73–119; region 3, 141–188; region 4, 237–296; re-
gion 5, 347–710 containing the first nucleotide-bind-
 .ing domain NBD1 ; region 6, 778–832; region 7,
885–936; region 8, 995–1280 containing the second
 .nucleotide binding domain NBD2 . The remaining
non-membrane regions 210–215, 318–325, 732–756
.and 958–973 were not considered since predictive
methods are poorly reliable on sequences shorter than
40 residues. In the case of mouse and rat Pgp,
homologous regions to those defined for human Pgp
 .have been considered. iii For each sequence, the
data are presented in terms of consensus, i.e., the
prediction was considered only when a residue is
predicted in the same state by both SOPMA and PHD
methods. It should be noticed that both PHD and
SOPMA methods predict a same conformational state
for most residues. The amino acids predicted in
a-helix, b-sheet and coil are presented in black, grey
 .and white boxes, respectively. iv Other residues
which do not belong to transmembrane regions were
not predicted in a consensus way by both SOPMA
and PHD methods, i.e., no conformational state was
 .reported for these residues. v Human, mouse and rat
sequences have been predicted separately and aligned
by primary sequence homology to highlight Pgp seg-
ments that are predicted in the same consensus state.
Fig. 5 shows that the agreement between the pre-
diction of the secondary structure of Pgp from differ-
ent species is very good, as can be expected from the
high level of sequence homology 78% identity be-
.tween the three sequences . Secondary structure pre-
dictions easily distinguish regular secondary struc-
tures from aperiodic ones, and the combination with
sequence alignment allows the discrimination of am-
biguously predicted regions. Although several regions
comprise poorly organized or ambiguously predicted
conformation states, Fig. 5 highlights frequent, rather
long, and conserved sequences predicted unambigu-
ously and simultaneously for the three sequences,
either as a helices 18 of such helices comprising at
. least four residues are observed , or as b-sheets 10
.segments with at least three residues or as aperiodic
 .segments 21 segments with at least four residues .
Because of the severe limitations described above for
the ratification of the predicted conformational state,
we assume that the secondary structure predicted for
these segments is the most probable one occurring in
native Pgp.
It should be noticed that the two major extra
membrane segments 347–710 and 995–1280 for
.human Pgp containing NBD1 and NBD2 Pgp do-
mains exhibit an alternance of predicted a-helix and
b-sheet and thus appear to belong to the arb struc-
tural class of proteins. This feature is common to
proteins that bind nucleotides through the ATP-bind-
w xing cassette defined by Walker et al., 7 . The posi-
tion of the nucleotide-binding domain glycine-rich
 .loops called motif A and presenting the consensus
w x  . w xAG –x 4 –G–K– ST sequence is indicated by a
heavy line on Fig. 5 segments 427–434 and 1070–
1077 for human NBD1 and NBD2 Pgp domains,
.respectively . These A motifs are both located be-
tween a highly probable b sheet and an a helix,
which corresponds to the topology of A motifs ob-
served in four nucleotide-binding proteins for which
the 3D structure is known and that are available on
Protein Data Bank database: adenylate kinase
 .  .3ADK , elongation factor TU 1ETU , guanylate
 . RAS  .kinase 1GKY , and p21 5P21 . Fig. 6 shows the
A motif sequence alignment for these four proteins
together with those of NBD1 and NBD2 domains of
Fig. 6. Primary and secondary structure comparison between A
motifs of known 3D structure and of the two Pgp A motifs. The
A motif of nucleotide binding domain present the consensus
w x  . w xAG –x 4 –G–K– ST sequence. The four nucleotide-binding
proteins taken into account are those for which the 3D coordi-
nates are available on NRL_3D database: adenylate kinase
 w x.  w x.3ADK, 41 , elongation factor TU 1ETU, 42 , guanylate
 w x. RAS  w x.kinase 1GKY, 43 , and p21 5P21, 44 . The secondary
structure has been deduced from 3D data by using the Kabsch
w xand Sander 45 method. The greyed box encircling the two last
 .sequences highlights the two predicted NBDs motif A from the
human Pgp. Open rectangles represent b sheets; filled black
rectangles represent a helices; dotted rectangles represent b
turns. A motifs have been aligned and the number on their left
indicates the first amino acid of the corresponding sequence
segment.
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human Pgp. Although the consensus primary se-
quence homology is limited to only three identical
residues, the predicted secondary structures for the
two human Pgp A motifs fit well with that observed
for the four crystallized proteins. Moreover, Fig. 7A
shows that the 3D structure of A motifs of these four
 .Fig. 7. Conformation of nucleotide-binding A motif. A , Super-
imposition of A motif of the four reference crystallized proteins
indicated in legend of Fig. 6. 3ADK, 1ETU, 1GKY, and 5P21 are
presented with, respectively, no nucleotide, GDP, GMP, and
X  .2-guanosine-5 - b ,g-imido triphosphate. When present, nu-
cleotides are represented with medium-size lines whereas back-
bones are shown with large-size lines. Side chains are drawn with
thin lines. The fit was performed for a-carbons of 22 amino acids
starting with the third position in the alignment. Root mean
˚  .square deviation at the a-carbon level is 0.93 A. B Predicted
topology for the two A motifs of human Pgp NBD1 and NBD2.
The main chain of the represented A motif fold was deduced
 .from the four A motifs presented in A . The amino acid position
is given for NBD1; when different, residues of NBD2 A motif
are given in parentheses.
reference proteins can be superimposed and fit with a
˚root mean square deviation of 0.93 A, i.e., they
exhibit a very close conformation. This demonstrates
that the structure of A motifs is common for all
available nucleotide-binding protein structures and
consequently, it appears highly probable that the A
motifs of Pgp NBD1 and NBD2 adopt the same
global fold. Thus, a model for the topology of the A
motifs has been built on the basis of the average
conformation of A motifs of known 3D structure.
This model is presented in Fig. 7B with the amino
acid sequence of human NBD1 and NBD2 A motifs
the sequence of the latter is between parenthesis
.when no identical residue is observed and it is also
transposable to the homologous rat and mouse A
motifs.
4. Discussion
To further understand the functional mechanism of
drug transportation, detailed structural data of P-
glycoprotein are indispensable. We have therefore
investigated the structure of human, rat and murine
Pgp by combining circular dichroism analysis and
secondary structure prediction from amino acid se-
quence analysis. The CD study was feasible because
of the availability of sufficient amount of highly
purified Pgp prepared by the procedure that we re-
w xported recently 3 , i.e., solubilization and purification
of Pgp in the presence of SDS followed by the
complete removal and exchange of SDS into DM.
The removal of SDS was achieved by the HAP-medi-
ated SDS removal method that we described recently
w x15 and that combines the effects of phosphate ions
and the hydrophobic tail of a non-ionic detergent to
displace SDS molecules from their protein-binding
sites during ceramic hydoxyapatite chromatography.
SDS is well known to delipidate membrane proteins
because of its ability to replace phopholipids bound
to proteins. Hence, our Pgp preparations are highly
depleted of lipids, and thus inactive in this state, as
w xalso reported by others 37,46 . This rises the ques-
tion of whether CD spectra of Pgp solubilized in DM
represent those of the native protein. The fact that the
reconstitution of DM-solubilized Pgp into liposomes
allows the restoration of both ATPase activity and
ww xATP-dependent drug transportation 3,15 , present
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xwork is a good indication that its global conforma-
tion should not be far from the native one, and that its
secondary structure should be the same. Moreover,
the recent electron microscopy observations of Pgp
showed that both DM-solubilized and lipid-recon-
stituted Pgp displayed similar shapes and dimensions
w x13 , indicating that DM does not disrupt the sec-
ondaryrtertiary structure of Pgp. The basal ATPase
activity of our reconstituted Pgp about 200 nmol
.ATPrminrmg Pgp is in the range or higher of that
w xreported by others 47,14 , but about 4 to 8 times
lower than that reported for Pgp preparations for
which no attempts to delipidate the protein were
w xmade 13,46,48 . Although several factors listed pre-
w xviously 3 may account for the explanation of these
differences in particular the lack of specific associa-
w x.tion with an unidentified phospholipid 37,49 , a
very probable explanation comes from the problem of
Pgp orientation in reconstituted liposomes. Indeed, it
is known that reconstitution into liposomes favors the
w xright-side out configuration for Pgp 13,46 . Further-
more, the reconstitution procedure of Rigaud et al.
used in this study is particularly efficient to obtain
right-side out orientation for glycoproteins, because
w xof the bulky hydrophilic sugar part 27 , and Rigaud
.J-L, personal communication . In that configuration,
Pgp NBDs are localized on the inner face of the
liposome and are thus not directly accessible to ATP.
Hence, measured ATPase activity should be mainly
due to some Pgp in the inside-out configuration. This
ratio between right-side out and inside-out orientation
of Pgp can also explain the 5-fold ATPase activity of
deglycosylated Pgp around 1000 nm ol
.ATPrminrmg protein . Indeed, in the absence of the
sugar moiety, the hydrophilicrhydrophobic unbal-
ance between the two extramembraneous parts of Pgp
is probably not sufficient enough to direct the orienta-
tion of Pgp during liposome formation. This yields
more Pgp in the inside-out configuration for which
NBDs are directly accessible to ATP, yielding a
higher ATPase activity than normal Pgp. The above
reconstitution features and the activation of Pgp by
various compounds render the estimation of Pgp en-
zymatic activity particularly difficult. Although fur-
ther careful investigations are needed to better evalu-
ate the reconstitution and the activities of Pgp, it is
clear that the sugar part of Pgp does not appear
essential for its activity.
4.1. Glycosylation of Pgp
Comparison of Pgp CD spectra recorded in DM
showed that the shape differences between the three
species are virtually abolished when the sugar part of
 .Pgp is removed by N-glycanase PNGase F treat-
ment, or not present as for rat Pgp prepared from
cells cultured in the presence of tunicamycin, which
inhibits glycosylation of newly-synthesized proteins
w x5 , or naturally not abundant like in murine Pgp.
This means that the differences in CD shape are
actually due to the presence of glycosylation. How-
ever, the relative contents in secondary structure de-
duced from spectral deconvolution is almost the same,
indicating that glycosylation has no significant effect
on the Pgp secondary structure. Moreover, it is note-
worthy that Pgp in SDS exhibited spectral features
very close to those of oligosaccharide-free Pgp in
DM and that all Pgp spectra from the three species
are almost superimposable in SDS. Two main conclu-
 .sions can be drawn from these observations: i the
spectrum of naturally low-glycosylated murine Pgp is
superimposable to the ones of highly glycosylated rat
and human in SDS, meaning that the sugar part of the
Pgp exerts a negligible contribution to CD by itself;
 .ii SDS probably abolishes the interaction between
the sugar part of Pgp with the core protein. It is thus
highly probable that the CD shape variations ob-
served for various Pgp in DM can be attributed to
some conformational changes due to sugar interac-
tions with the protein core. The above conclusions
are in agreement with what has been reported for
most glycosylated proteins studied by CD see for
example the anion transport protein of the human
w xerythrocyte membrane, 50,51 ; the cobra venom fac-
w x w x.tor, 52 ; the water channel CHIP28 protein, 53 ,
although dramatic changes have been observed for
some proteins involved in recognition processes such
w xas Human CD2 19 . Moreover, it has been reported
that mutant human Pgp that lack all the three N-lin-
ked glycosylation sites in the first extracytoplasmic
loop provided drastically reduced drug-resistant
transfectants, suggesting that the sugar moiety may
contribute to the correct folding andror proper rout-
ing of Pgp, and its stabilization en route to or within
w xthe plasma membrane 4 . This feature seems to be
w xcommon to cell surface proteins 54 . From a func-
tional point of view, it is known that N-linked glyco-
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sylation can influence many properties of proteins,
including intracellular transport, biological activity,
stability and antigenicity. In some cases, the biologi-
cal effect of N-linked glycosylation on a glycoprotein
depends on the particular site of glycosylation within
the protein chain. In the case of Pgp studied here,
several results strongly suggest that oligosaccharide-
 .free Pgp is fully functional: i the purified rat degly-
cosylated Pgp reconstituted in liposomes exhibited
w3 xsimilar ATP-dependent H -vinblastine uptake to that
 .of the native glycosylated Pgp; ii rat hepatoma
AS30-DrCOL10 cells cultured in the presence of
tunicamycin are resistant to colchicin although Pgp is
 .actually non-glycosylated; iii murine Pgp is natu-
rally poorly glycosylated but it is fully functional,
i.e., conferring drug resistance to lymphoid leukemia
P388rADR25 cells. Consequently, all these struc-
 .tural and functional results suggest i that the re-
moval of the sugar part of Pgp does not result in a
significant destabilization of the secondary and ter-
 .tiary structure of Pgp, and ii that glycosylation of
Pgp is not essential for its functioning, although a
fine tuning of the Pgp activity by the level of glyco-
sylation is not excluded.
4.2. Effect of SDS on Pgp
It has been reported in the literature that SDS tends
w xto increase the protein a-helix content 55 and to
w xdecrease the b-structure 56–58 while for some pro-
teins, no alteration of secondary structure was ob-
w xserved 59,60 . It is remarkable that in the case of
Pgp, the comparison between Pgp CD data in DM
and in SDS clearly indicates that any conformation
differences are minor. This is particularly obvious in
the case of murine Pgp. Moreover, SDS does not
induce a significant modification in the percentage of
each type of secondary structure deduced from CD
spectral analysis. Thus, besides the effect of SDS on
the sugar–Pgp core interaction discussed above, these
findings suggest that these slight spectral changes are
due to limited perturbation of the tertiary structure of
Pgp by SDS. According to the proposal for SDS–
w xgalactosidase interaction 61 , it is thought that SDS
molecules bind the outer surface of the Pgp without
disrupting the protein core. This is fully compatible
with the relative easiness to restore Pgp function
 w x.upon removal of SDS exchange into DM, 15 and
w xreconstitution into liposomes 3 , indicating that SDS
does not induce extensive denaturation of Pgp. By the
way, this SDS binding, which is limited to the outer
surface of the protein, may be a common phe-
nomenon which is not only limited to membrane
proteins. Indeed, we have recently shown that pro-
teins such as lysozyme and glutamate dehydrogenase
can easily recover their full activities after the com-
plete removal of SDS or its exchange into another
w xmild detergent such as dodecyl maltoside 15 .
4.3. Secondary structure of Pgp
The far-UV CD spectra of Pgp are dominated by
the contribution of a-helical structure with prominent
bands at 222 and 208 nm. The secondary structure of
Pgp deduced from circular dichroism spectra using
w xthe Varselec method 21 is similar for the three
species and composed of 38–43% a-helix, 16–19%
b-sheets, 14–15% b-turn, and 26–28% of other
structures, whatever the Pgp species and its level of
 .glycosylation are Table 1 . As discussed above, both
glycosylation and detergents slightly change the shape
of Pgp CD spectra, but have no significant effect on
the secondary structure content. In addition, it should
be mentioned that whatever the Pgp species, either
glycosylated or not, and whatever the detergent used,
satisfactory analyses of CD spectra were always
achieved after elimination of the same three proteins
from the basic set of 33 reference proteins: poly
glutamic acid, triose phosphate isomerase and
hemerythin. This constitutes an indication of the con-
sistency between the various Pgp spectra. In accor-
w xdance with the statement of Johnson 16 , CD spectra
should be recorded down to at least 184 nm to yield
statistically significant estimates of multiple classes
of secondary structure. Moreover, considering that
SDS is known to induce some conformational change
in protein, the most accurate data were those obtained
with human Pgp the CD spectra of which were
recorded down to 183 nm in the presence of DM.
Although it should be kept in mind that secondary
structure estimation was made using soluble non-gly-
cosylated reference proteins of known secondary
structure and that the Pgp integrated into micelles
may display some unexpected CD contribution, the
most reliable estimation of Pgp secondary structure
contents is 43% a-helix, 16% b-sheets 10% anti-
( )M. Dong et al.rBiochimica et Biophysica Acta 1371 1998 317–334332
.parallel, 6% parallel , 15% b-turn, and 26% other
structures. These proportions appear quite different
from those estimated by attenuated total reflection
FTIR for Pgp reconstituted into liposomes 32% a-
helix, 26% b-sheet, 29% b-turn and 13% unordered
w x.structure, 14 . It should be kept in mind that both
CD and FTIR methods of secondary structure content
estimation used structural parameters deduced from
soluble proteins of known structure, and that it could
not be ruled out that some unexpected contribution
due to the membranous part of Pgp andror Pgp–lipid
interaction may skew these estimations. However, the
secondary structure proportions deduced from CD
data agree quite well with those predicted from Pgp
w xamino acid sequence combining PHD 24 and
w xSOPMA 25 prediction methods, i.e., 48% a-helix,
 .16% b-sheets, and 36% coil structures see below .
This consistency reinforces the reliability of sec-
ondary structure prediction which allows the most
probable nature and localization of secondary struc-
ture elements along the Pgp sequence.
Pgp contains 12 transmembrane regions, the pre-
cise topology of which is still a matter of controversy
w x39,62,40 . Because secondary structure predictive
methods are known not to be accurate within mem-
brane regions, we have taken into account the inter-
membrane regions as proposed by the classical model
w xof Chen et al., 39 . Conversely, prediction methods
such as PHD and SOPMA are very effective on
globular protein, especially when they are used in
combination: a success rate as high as 82% for jointly
w xpredicted residues can then be reached 25 . The
predictions of non-membrane segments of Pgp re-
ported in Fig. 5 were made very carefully as de-
scribed in Section 3. In particular, ambiguously pre-
dicted residues were not reported in this Figure which
thus presents only reliable predictions for a-helix,
b-sheet, and coil conformations. Moreover, a supple-
mentary index of reliability of the predicted structure
is given by the three aligned sequences of Pgp.
Indeed, the prediction of the same conformational
state for a particular residue that occupies the same
position in the three sequences increases its probabil-
ity to be correctly predicted. In our opinion, the
present prediction represents an accurate framework
of the actual Pgp secondary structure which consti-
tute a good basis for further 3D Pgp structure model-
ing.
4.4. Modeling of nucleotide binding A motifs of Pgp
Global structural models of ATP-binding domains
of periplasmic permeases have been proposed by
w xanalogy to the adenylate kinase 3D structure 8,13 .
The precise knowledge of Pgp secondary structure
allows a better specification of the nucleotide-binding
A motifs for which secondary structure exhibits a
strong similarity with A motifs of known crystallized
 .proteins Fig. 6 . The 3D structures of A motifs of
the four nucleotide-binding proteins exhibit superim-
posable conformation Fig. 7A, adenylate kinase
 .  .3ADK , elongation factor TU 1ETU , guanylate
 . RAS  ..kinase 1GKY , and p21 5P21 , demonstrating
that the A motif fold is common for these four
proteins and it appears highly probable that the A
motifs of Pgp NBD1 and NBD2 adopt the same
global fold. A precise model for the folding of the
Pgp A motifs have thus been built by analogy with
 .known A motif folds Fig. 7B . It should be noticed
that three of the four nucleotide-binding proteins used
for modeling have been crystallized with a nu-
cleotide, as shown in Fig. 7A. It is clear that the three
nucleotides are localized near the turn between the
b-sheet and a-helix of the A motif. From these
observations, it is not possible to specify the position
of ATP in the A motifs of Pgp, but it seems probable
that ATP binds closed to the connecting segment
between the b-sheet and the a-helix. This region is
thus a good target for punctual mutations in order to
localize the residues involved in ATP binding. This
approach, combined with fluorescence nucleotide
analogues binding studies such as those reported in
our recent work concerning the recombinant NBD2
w xof mouse Pgp 63 , would bring further insight in the
understanding of the Pgp structure–function relation-
ship.
5. Conclusion
The present work is the first report of CD analyses
of the Pgp structure and the structural effect of
glycosylation on Pgp. By combining the experimental
data from circular dichroism and the predicted struc-
ture from the amino acid sequence, we have specified
the most probable localization of secondary structure
elements along the Pgp sequence. These data repre-
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sent a useful template for any 3D structure modeling
of Pgp and it is well illustrated here by the modeling
of Pgp A motifs of ATP binding sites. This is a step
towards tertiary structure modeling of Pgp for which
more experimental data are needed, such as the
knowledge of the tertiary structure of Pgp based on
2D crystals.
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